{"id":185,"date":"2021-05-13T08:26:42","date_gmt":"2021-05-13T08:26:42","guid":{"rendered":"http:\/\/tech3.mypagedemo.com\/cm-plus\/?p=185"},"modified":"2021-05-13T08:26:44","modified_gmt":"2021-05-13T08:26:44","slug":"exelixis-cabometyx-scores-backing-from-ipsen-in-thyroid-cancer-with-full-data-release-set-for-asco","status":"publish","type":"post","link":"https:\/\/tech3.mypagedemo.com\/cm-plus\/exelixis-cabometyx-scores-backing-from-ipsen-in-thyroid-cancer-with-full-data-release-set-for-asco.html","title":{"rendered":"Exelixis&#8217; Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO"},"content":{"rendered":"<p>Exelixis&#8217; flagship oncology drug Cabometyx has attracted a pharma partner to take it into a new type of cancer thanks to promising results in a pivotal trial.<\/p>\n<div id=\"content-embed-one-wrapper\">\n<div id=\"content-embed-one\"><\/div>\n<\/div>\n<p>In a late-stage trial in patients with a form of thyroid cancer, Cabometyx posted\u00a0promising\u00a0results, executives say, prompting French pharma Ipsen to step in and help get the drug across the finish line with global regulators.<\/p>\n<p>Ipsen\u00a0has\u00a0<a href=\"https:\/\/www.ipsen.com\/press-releases\/ipsen-opts-in-to-join-exelixis-with-ongoing-development-of-cabometyx-for-people-living-with-a-form-of-thyroid-cancer-based-on-promising-interim-results\/\" rel=\"nofollow\">exercised its option<\/a>\u00a0to collaborate with Exelixis on Cabometyx\u2019s pivotal phase 3 clinical trial, known as COSMIC-311, studying the medicine in patients with radioiodine-resistant differentiated thyroid cancer who have progressed after prior treatment with vascular endothelial growth factor receptor (VEGFR)-targeted therapies.<\/p>\n<section class=\"section-container\">\n<header class=\"header-align\">\n<h2><span class=\"header-text\">LIMITED-TIME ON-DEMAND WEBINAR<\/span><\/h2>\n<\/header>\n<h2 class=\"title-cta\">\u201cNext Best\u201d Brings Intelligence to the Point of Execution<\/h2>\n<div class=\"body-text\">In this webinar, we explore how \u201cNext Best\u201d recommendations utilize the power of Connected Intelligence\u2122 to take the complexity out of omnichannel customer engagement.<\/div>\n<footer class=\"footer-align\">\n<div class=\"cta-button-IQVIA-051021\"><a href=\"https:\/\/questex.blueconic.net\/s\/5iB?profileid=72b31c18-6b22-49c9-95ed-6df30fb956a9\" target=\"_blank\" rel=\"nofollow noopener\">REGISTER NOW<\/a><\/div>\n<\/footer>\n<\/section>\n<div id=\"mobile-ad-wrapper\">\n<div id=\"ad-slot_1__mobile\"><\/div>\n<\/div>\n<p>Ipsen is anteing up in the thyroid cancer use\u00a0thanks to\u00a0\u201cpromising and clinically meaningful results\u201d in the trial, Howard Mayer, Ipsen&#8217;s R&amp;D head, said in a statement.<\/p>\n<p>In late December, Exelixis\u00a0<a href=\"https:\/\/ir.exelixis.com\/news-releases\/news-release-details\/exelixis-announces-cabozantinib-significantly-improved\" rel=\"nofollow\">said<\/a>\u00a0interim results from COSMIC-311 showed the tyrosine kinase inhibitor reduced the risk of disease progression or death by 78%, meeting its co-primary endpoint of progression-free survival. For the study, investigators enrolled\u00a0approximately 300 patients at 150 sites globally. Patients received either cabozantinib\u00a0or placebo once daily.<\/p>\n<p>After the interim results, the FDA awarded the drug a breakthrough therapy designation in February. Now, Exelixis and Ipsen plan to present detailed results from the phase 3 trial at the ASCO Annual Meeting, taking place beginning on June 4. Ipsen will have access to its full set of results, which it will use for potential future regulatory submissions.<\/p>\n<p>The company\u00a0previously had\u00a0a\u00a0partnership with Exelixis to commercialize Cabometyx\u2014authorized in over 50 countries for the treatment of kidney cancer\u2014outside the U.S. and Japan.<\/p>\n<p><strong>RELATED:\u00a0<\/strong><strong><a href=\"https:\/\/www.fiercepharma.com\/marketing\/asco-gu-2-year-data-jury-s-still-out-kidney-cancer-race-between-opdivo-cabometyx-and\">With 2-year data, the jury&#8217;s still out on the kidney cancer race between Opdivo-Cabometyx and Keytruda-Inlyta<\/a><\/strong><\/p>\n<p>Roughly 44,000 new cases of thyroid cancer will be diagnosed in the U.S. this year, Exelixis says. Differentiated thyroid tumors make up most of all thyroid cancers and are usually treated with surgery, followed by treatment with radioiodine.<\/p>\n<p>But roughly 5% to 15% of those tumors are resistant to the treatment, leaving patients with few treatment options to improve life expectancy, Exelixis says.<\/p>\n<p><strong>RELATED:\u00a0<a href=\"https:\/\/www.fiercepharma.com\/pharma\/bristol-myers-preps-2nd-kidney-cancer-combo-nod-as-opdivo-cabometyx-duo-slash-death-risk-40\">ESMO: Bristol Myers preps 2nd kidney cancer combo nod as Opdivo-Cabometyx duo slashes death risk 40%<\/a><\/strong><\/p>\n<p>Aside from its Ipsen collab, Exelis has partnerships on its cancer medicines with Bristol Myers Squibb and Roche.<\/p>\n<p>Earlier this year, the FDA authorized Cabometyx in combination with Bristol Myers Squibb\u2019s\u00a0<a href=\"https:\/\/www.drugs.com\/opdivo.html\" rel=\"nofollow\">Opdivo<\/a>\u00a0for the treatment of patients with advanced renal cell carcinoma, setting up a\u00a0<a href=\"https:\/\/www.fiercepharma.com\/marketing\/bristol-myers-exelixis-get-fda-fast-lane-for-opdivo-cabometyx-combo-kidney-cancer\">showdown<\/a>\u00a0between that combo and the Merck and Pfizer\u2019s cocktail of Keytruda and Inlyta. In previously untreated kidney cancer, the Opdivo-Cabometyx combo slashed the risk of death by 34% compared with Pfizer\u2019s older drug Sutent.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Exelixis&#8217; flagship oncology drug Cabometyx has attracted a pharma partner to take it into a new type of cancer thanks to promising results in a pivotal trial. In a late-stage trial in patients with a form of thyroid cancer, Cabometyx posted\u00a0promising\u00a0results, executives say, prompting French pharma Ipsen to step in and help get the drug [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":186,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"featured_image_src":{"landsacpe":["https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-content\/uploads\/2021\/05\/CABOMETYX-800x445.jpg",800,445,true],"list":["https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-content\/uploads\/2021\/05\/CABOMETYX-463x348.jpg",463,348,true],"medium":["https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-content\/uploads\/2021\/05\/CABOMETYX-300x217.jpg",300,217,true],"full":["https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-content\/uploads\/2021\/05\/CABOMETYX.jpg",800,578,false]},"_links":{"self":[{"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/posts\/185"}],"collection":[{"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/comments?post=185"}],"version-history":[{"count":1,"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/posts\/185\/revisions"}],"predecessor-version":[{"id":187,"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/posts\/185\/revisions\/187"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/media\/186"}],"wp:attachment":[{"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/media?parent=185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/categories?post=185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tech3.mypagedemo.com\/cm-plus\/wp-json\/wp\/v2\/tags?post=185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}